|Bid||0.0000 x 1100|
|Ask||0.0000 x 1200|
|Day's Range||0.9500 - 1.2400|
|52 Week Range||0.6191 - 15.4801|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.78|
Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of its reverse merger with Zafgen, Inc. (ZFGN). The combined, publicly traded clinical-stage biotechnology company will operate under the name Larimar Therapeutics, Inc. and its shares will commence trading on the Nasdaq Global Market on May 29, 2020, under the ticker symbol “LRMR.”
Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein.
A look at some stocks Benjamin Graham might have liked Continue reading...